Real-world management of immune-related adverse events in the community setting

被引：0
|
作者：
Johnson, D. B. [1 ]
Bruno, D. [2 ]
Rioth, M. [3 ]
Zhang, C. [4 ]
Palaia, J. [5 ]
Pisupati, R. [6 ]
Bond, C. [7 ]
Rosenblatt, L. C. [8 ]
Broome, R. G. [9 ]
Teka, M. [10 ]
Kluger, H. [11 ]
机构：
[1] Vanderbilt Univ, Hematol Oncol, Med Ctr, Nashville, TN USA
[2] Case Western Reserve Univ, Med, Univ Hosp, Cleveland, OH USA
[3] Syapse, Med Oncol, San Francisco, CA USA
[4] Syapse, Data Insights, San Francisco, CA USA
[5] BMS Bristol Myers Squibb, Hlth Econ & Outcomes Res, Princeton, NJ USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] BMS Bristol Myers Squibb, Epidemiol, Princeton, NJ USA
[8] Bristol Myers Squibb, WW Hlth Econ & Outcomes Res US Market, Lawrenceville, GA USA
[9] Syapse, Clin Abstract, San Francisco, CA USA
[10] Syapse, Insights Analyt, San Francisco, CA USA
[11] Yale Canc Ctr, Oncol, Breast Ctr, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1675
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1582P
引用
收藏
页码：S1268 / S1269
页数：2
相关论文
共 50 条
  • [41] ANALYSIS OF IMMUNE RELATED ADVERSE EVENTS IN NSCLC PATIENTS RECEIVING DURVALUMAB AFTER CHEMORADIOTHERAPY IN THE REAL-WORLD CLINICAL SETTING
    Fujita, Kohei
    Yamamoto, Yuki
    Kanai, Osamu
    Okamura, Misato
    Nakatani, Koichi
    Mio, Tadashi
    RESPIROLOGY, 2019, 24 : 50 - 50
  • [42] Current landscape and tailored management of immune-related adverse events
    Liu, Wenhui
    Luo, Zhiying
    Liu, Yiping
    Sun, Bao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [43] Cardiovascular immune-related adverse events: Evaluation, diagnosis and management
    Liu, Yingxian
    Wu, Wei
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (04) : 232 - 240
  • [44] Checkpoint Inhibitors Common immune-related adverse events and their management
    Gordon, RuthAnn
    Kasler, Mary Kate
    Stasi, Kristen
    Shames, Yelena
    Errante, Mimma
    Ciccolini, Kathryn
    Lucas, Anna Skripnik
    Raasch, Pam
    Fischer-Cartlidge, Erica
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (02) : 45 - 52
  • [45] Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
    Raschi, Emanuel
    Gatti, Milo
    Gelsomino, Francesco
    Ardizzoni, Andrea
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    TARGETED ONCOLOGY, 2020, 15 (04) : 449 - 466
  • [46] Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver
    Shen, Shufang
    Dai, Huaxing
    Fei, Ziying
    Chai, Yu
    Hao, Yu
    Fan, Qin
    Dong, Ziliang
    Zhu, Yujie
    Xu, Jialu
    Ma, Qingle
    Han, Xiao
    Xu, Ligeng
    Peng, Fei
    Liu, Zhuang
    Wang, Chao
    ACS NANO, 2021, 15 (05) : 9111 - 9125
  • [47] Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
    Emanuel Raschi
    Milo Gatti
    Francesco Gelsomino
    Andrea Ardizzoni
    Elisabetta Poluzzi
    Fabrizio De Ponti
    Targeted Oncology, 2020, 15 : 449 - 466
  • [48] Management of Steroid-Refractory Immune-Related Adverse Events
    Watson, Marley L.
    Beardslee, Tyler
    ONCOLOGY-NEW YORK, 2019, 33 (08): : 304 - 306
  • [49] Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
    Weber, Jeffrey S.
    Kaehler, Katharina C.
    Hauschild, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2691 - 2697
  • [50] Oral Immune-Related Adverse Events - Current Concepts and their Management
    Asan, Mohamed Faizal
    Castelino, Renita Lorina
    Babu, Subhas G.
    Rao, Kumuda
    Pandita, Vaibhav
    ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2021, 8 (06) : 604 - 609
12345